PCH
KALV

Polar Capital Holdings’s KalVista Pharmaceuticals KALV Stock Holding History

Polar Capital Holdings’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-617,180
Closed -$14.8K – 361
2021
Q2 		$14.8K Sell
617,180
-389,875
-39% -$10.2M 0.06% 198
2021
Q1 		$25.9M Buy
+1,007,055
New +$26.5M 0.16% 134

Other funds holding KALV

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Polar Capital Holdings's KALV Position: Q3 2021 in Review

Polar Capital Holdings sold out of KalVista Pharmaceuticals (KALV) in Q3 2021, closing a stake of 617,180 shares — an estimated $14.8K sold.

Polar Capital Holdings first reported a position in KALV in Q1 2021 and held it in 2 quarters. The position peaked at $25.9M in Q1 2021. 105 funds tracked by Wall St. Rank hold KALV as of Q3 2021.

  • Polar Capital Holdings reported no remaining KalVista Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Polar Capital Holdings sold 617,180 KalVista Pharmaceuticals shares in Q3 2021, an estimated $14.8K.
  • Polar Capital Holdings first reported a position in KalVista Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Polar Capital Holdings's KalVista Pharmaceuticals position peaked at $25.9M in Q1 2021.
  • 105 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2021.

Based on Polar Capital Holdings's 13F filing for Q3 2021, filed 15 Nov 2021.